Welcome to our dedicated page for Vaxcyte SEC filings (Ticker: PCVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
VAXCYTE, INC. Schedule 13G/A discloses that RA Capital-related reporting persons beneficially owned 12,974,599 shares of Common Stock as of 03/31/2026. The ownership reported includes 11,199,089 shares held by RA Capital Healthcare Fund, 1,500,000 Pre-Funded Warrants exercisable into Common Stock, and 275,510 shares held by RA Capital Nexus Fund. The filing states the percentage basis uses 143,920,361 shares outstanding as of 02/20/2026.
Janus Henderson Group plc filed Amendment No. 9 to a Schedule 13G/A reporting beneficial ownership of 16,575,875 shares of Vaxcyte, Inc. common stock (11.5% of the class) as of 03/31/2026. The filing states the Asset Managers exercise shared voting and dispositive power over these shares on behalf of managed client portfolios; the Asset Managers disclaim rights to dividends or sale proceeds.
Vaxcyte, Inc. reported a larger quarterly loss as it accelerates late‑stage vaccine development and manufacturing build‑out. For the three months ended March 31, 2026, net loss widened to $320.6 million, or $2.30 per share, from $140.7 million a year earlier, driven mainly by a sharp rise in research and development spending.
R&D expenses more than doubled to $312.8 million as the company advanced its 31‑valent pneumococcal conjugate vaccine VAX‑31 through multiple Phase 3 adult trials and a Phase 2 infant study, while progressing its Group A Strep candidate VAX‑A1 toward a Phase 1 start. General and administrative costs were stable at $33.1 million.
Vaxcyte ended the quarter with $2.7 billion in cash, cash equivalents and investments and stockholders’ equity of $3.0 billion, bolstered by $601.8 million in net proceeds from a February 2026 follow‑on offering. Operating activities used $280.6 million of cash in the quarter. Management states this liquidity should fund operating and capital needs for at least 12 months.
Vaxcyte, Inc. reported first-quarter 2026 results and a broad clinical and manufacturing update. The company is fully enrolled in its three adult Phase 3 OPUS trials of VAX-31 and expects topline OPUS-1 data in the fourth quarter of 2026, with OPUS-2 and OPUS-3 results in the first half of 2027. An infant Phase 2 dose-finding study of VAX-31 has completed enrollment, with topline data from the primary series and booster expected by the end of the first half of 2027. Vaxcyte plans to start a Phase 1 adult trial of its Group A Strep vaccine candidate VAX-A1 in mid-2026. The company completed a February 2026 equity offering of 12,650,000 shares at $50.00 per share, contributing to $2.74 billion in cash, cash equivalents and investments as of March 31, 2026. First-quarter R&D expenses rose to $312.8 million, and net loss widened to $320.6 million, or $2.30 per share.
FMR LLC reports beneficial ownership of Vaxcyte common stock totaling 16,451,061.32 shares, representing 11.4%. The filing is an Amendment No. 9 to a Schedule 13G/A that lists voting and dispositive powers held by FMR LLC and by Abigail P. Johnson, and references a 13d-1(k) agreement and a power of attorney incorporated by reference.
Vaxcyte, Inc. chief operating officer Jim Wassil reported an open-market sale of 2,250 shares of common stock at a weighted-average price of $56.831 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. After this sale, he directly holds 160,744 shares of Vaxcyte common stock.
PCVX insider reported planned sales of company common stock. The filing lists two sale notices: 7,395 shares for $435,438.31 dated 03/10/2026 and 2,250 shares for $131,475.60 dated 04/01/2026, totaling $566,913.91. The filing also lists recent issuer vesting events (RSU and ESPP) with specified share counts and vesting dates.
Vanguard Capital Management reported beneficial ownership of 7,252,053 shares of Vaxcyte Inc. common stock, representing 5.03% of the class. The filing shows Vanguard has sole power to dispose of 7,252,053 shares and sole voting power over 985,352 shares. The filing is signed by Ashley Grim on 04/30/2026.
Vaxcyte, Inc. is holding its 2026 virtual Annual Meeting on June 15, 2026 at 8:30 a.m. Pacific Time. Stockholders of record as of April 20, 2026, when 144,387,225 common shares were outstanding, may vote online or by proxy.
Stockholders will vote on three items: electing three Class III directors to serve until the 2029 meeting, ratifying Deloitte & Touche LLP as independent auditor for 2026, and approving on an advisory basis the compensation of named executive officers. The Board recommends voting in favor of all three proposals.
The filing details Vaxcyte’s governance structure, including a majority‑independent board, fully independent key committees, and formal risk‑oversight responsibilities. It also highlights stock ownership guidelines, restrictions on hedging and pledging, and a director pay program combining cash retainers with annual equity grants and change‑in‑control vesting.
The Compensation Committee notes that only 64% of votes supported the 2025 say‑on‑pay proposal, describes extensive outreach to major investors, and commits to limiting one‑time executive equity awards to extraordinary, well‑justified situations while emphasizing ongoing pay‑for‑performance alignment.